FY2023 EPS Estimates for Lonza Group AG Cut by Analyst (OTCMKTS:LZAGY)

Lonza Group AG (OTCMKTS:LZAGY – Get Rating) – Stock analysts at KeyCorp decreased their FY2023 EPS estimates for Lonza Group in a research report issued to clients and investors on Monday, May 22nd. KeyCorp analyst P. Knight now anticipates that the company will earn $1.68 per share for the year, down from their previous forecast of $1.76. The consensus estimate for Lonza Group’s current full-year earnings is $1.72 per share. KeyCorp also issued estimates for Lonza Group’s FY2024 earnings at $2.14 EPS.

LZAGY has been the topic of a number of other research reports. Stifel Nicolaus assumed coverage on shares of Lonza Group in a research note on Wednesday, May 17th. They issued a “hold” rating on the stock. William Blair reissued an “outperform” rating on shares of Lonza Group in a research note on Friday, February 10th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $680.50.

Lonza Group Price Performance

Shares of LZAGY opened at $62.57 on Wednesday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.27 and a current ratio of 1.86. The firm’s 50-day moving average is $62.39 and its two-hundred day moving average is $57.07. Lonza Group has a twelve month low of $43.85 and a twelve month high of $65.96.

Lonza Group Increases Dividend

The business also recently disclosed a dividend, which will be paid on Friday, May 26th. Shareholders of record on Wednesday, May 10th will be issued a dividend of $0.108 per share. This is a positive change from Lonza Group’s previous dividend of $0.09. This represents a yield of 0.17%. The ex-dividend date is Tuesday, May 9th.

About Lonza Group

(Get Rating)

Lonza Group AG is engaged in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle.